MLC901 in Moderate Traumatic Brain Injury — ANDROMEDA

Moderate Traumatic Brain Injury Clinical Trial

Official title:
Safety and Efficacy of MLC901 (NeuroAiD Ii) in Patients With Moderate TBI: A Randomized Double Blind Placebo Controlled Trial

Status Recruiting

Clinical Trial Summary

This study wants to evaluate whether MLC901 will help improve the condition of adult patients with moderate traumatic brain injury.

Clinical Trial Description

This is a double blind placebo controlled randomized trial to determine whether giving MLC901 for 6 months will improve the outcomes in a adult patients with moderate traumatic brain injury. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04766281
Study type	Interventional
Source	University of the Philippines
Contact	Annabell E Chua, MD
Phone	+632-85242338
Email	aechua@up.edu.ph
Status	Recruiting
Phase	Phase 4
Start date	May 1, 2021
Completion date	July 31, 2024

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05108909` - Rapid Diagnosis and Prognosis Recognition of Imaging and Biomarkers in Mild to Moderate Traumatic Brain Injury
Completed	`NCT04641767` - BIOmarkers of TRAumatic Brain Injury Spain (BIOTRABIS)
Completed	`NCT01398566` - Clinical Trial of a Rehabilitation Game - SuperBetter	N/A
Recruiting	`NCT04900168` - Intracranial Pressure Monitoring in Moderate Traumatic Brain Injury
Recruiting	`NCT04124029` - Contributions of mTBI to Neurodegeneration Due to Chronic Traumatic Encephalopathy (CTE) and Alzheimer's Disease (AD)
Recruiting	`NCT06222502` - Walking After Traumatic Brain Injury in Older Adults	N/A